Literature DB >> 10027511

Discrimination and self-administration of nicotine by inbred strains of mice.

I P Stolerman1, C Naylor, G I Elmer, S R Goldberg.   

Abstract

These studies aim to characterize the discriminative stimulus effects of nicotine in two inbred strains of mice that differ in many pharmacological responses, and to investigate the feasibility of IV self-administration studies with nicotine in one of the strains. For discrimination studies, three groups of C57BL/6 and one group of DBA/2 mice were trained in a two-lever operant conditioning paradigm with a tandem VI-30" FR-10 schedule of food reinforcement. After 40 training sessions, accuracy reached 57.5, 77.5 and 90.0% in C57BL/6 mice trained with (-)-nicotine (SC) in doses of 0.4, 0.8 and 1.6 mg/kg, respectively (n = 8). DBA/2 mice trained with 0.8 mg/kg nicotine attained similar (73.3 %) accuracy (n = 9). Results from extinction tests showed that all groups of mice yielded orderly dose-response curves for nicotine (0.03-1.6 mg/kg), but stimulus control remained notably weaker for the mice trained with 0.4 mg/kg nicotine than for any other group. Overall rates of responding in the undrugged state were lower for DBA/2 than for C57BL/6 mice; DBA/2 mice were also slightly less sensitive than C57BL/6 mice to the response rate-reducing effect of nicotine. The nicotine antagonist mecamylamine (1.5 mg/kg SC) blocked the discriminative stimulus effect of the training dose of nicotine in all groups. The results of the IV self-administration study suggest that nicotine (0.1 mg/kg) can serve as a positive reinforcer in drug-naive C57BL/6J mice (n = 13). Behaviour maintained by 0.1 mg/kg nicotine injections was significantly greater than behaviour maintained by vehicle injections, and it was maintained under an intermittent schedule of reinforcement (FR4). The methods described provide possible approaches for genetic analyses of strain differences in sensitivity to the discriminative and reinforcing stimulus properties of nicotine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027511     DOI: 10.1007/s002130050837

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

Review 2.  Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement.

Authors:  Nadia Chaudhri; Anthony R Caggiula; Eric C Donny; Matthew I Palmatier; Xiu Liu; Alan F Sved
Journal:  Psychopharmacology (Berl)       Date:  2005-10-21       Impact factor: 4.530

3.  Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence.

Authors:  Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2006-08-24       Impact factor: 4.530

4.  Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

Authors:  Benoit Forget; Carrie Wertheim; Paola Mascia; Abhiram Pushparaj; Steven R Goldberg; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

5.  Nicotine as a typical drug of abuse in experimental animals and humans.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-10-05       Impact factor: 4.530

6.  Multiple nicotine training doses in mice as a basis for differentiating the effects of smoking cessation aids.

Authors:  Colin S Cunningham; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2013-03-14       Impact factor: 4.530

7.  Qualitative differences between C57BL/6J and DBA/2J mice in morphine potentiation of brain stimulation reward and intravenous self-administration.

Authors:  Greg I Elmer; Jeanne O Pieper; Lindsey R Hamilton; Roy A Wise
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

8.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

9.  The discriminative stimulus effects of i.v. nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.

Authors:  Megan J Moerke; Andy Z X Zhu; Rachel F Tyndale; Martin A Javors; Lance R McMahon
Journal:  Neuropharmacology       Date:  2016-12-08       Impact factor: 5.250

Review 10.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.